Gilead leaps ahead with FDA app for PI3K cancer killer FierceBiotech As the biotech giant had said was a possibility, Gilead is seeking an early approval for idelalisib to combat indolent cases of non-Hodgkin's lymphoma (NHL) that fail to respond to rituximab and alkylating-agent chemotherapies. Foster City, CA-based ... Gilead Seeks FDA Approval for Idelalisib Idelalisib NDA Submitted for Indolent Non-Hodgkin's Lymphoma Gilead Submits NDA for Idelalisib |
